🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Incidence and Clinical Features of Breakthrough Pain After Brachial Plexus Block in Diabetic Patients

Recruitingn/aAges 18 Years - 80 YearsAllSecond Hospital of Shanxi Medical University
NCT07833930 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational study aims to determine the incidence and clinical characteristics of rebound-breakthrough pain after ultrasound-guided brachial plexus block in adult patients with type 2 diabetes mellitus. Adult patients undergoing elective upper-extremity surgery are divided into a type 2 diabetes group and a non-diabetic control group. Baseline clinical data and pain-related outcomes are collected after nerve block. This work may provide evidence for optimizing perioperative pain management for diabetic patients receiving brachial plexus block.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 18 years or older * Undergoing elective upper-extremity surgery * Planned for ultrasound-guided brachial plexus block with 0.375% ropivacaine * Able to cooperate with pain assessment and follow-up within 48 hours after block * Written informed consent obtained Exclusion Criteria: * Allergy or contraindication to amide-type local anesthetics * Pre-existing peripheral neuropathy of the affected upper limb * Chronic regular use of opioids before surgery * Coagulopathy or infection at the block puncture site * Cognitive dysfunction unable to complete NRS pain evaluation * Pregnancy or lactation * Incomplete clinical data expected during follow-up
💊

What it tests

  • Not listed
📍

Where

1 site
Second Hospital of Shanxi Medical University
Taiyuan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy